2026
article
OpenAlex
Daniel Sentana‐Lledo, Avina Rami, Caiwei Zhong, Miguel Muniz et autres
PURPOSE: 177Lu-PSMA-617 (LuPSMA) is an approved prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy for men with metastatic castration-resistant prostate cancer (mCRPC). Older patients, particularly octogenarians, represent a substantial proportion of men with mCRPC but have been traditionally underrepresented in key registrational trials of …
us
(code pays fourni par la source)
2026
article
OpenAlex
Narmeen S Rashid, Caiwei Zhong, Wanling Xie, Hailey Stoltenberg et autres
us
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Elizabeth Tchitchkan, Caiwei Zhong, W. Xie, Rajesh Anumolu et autres
138 Background: LuPSMA is a PSMA-targeted radiopharmaceutical used to treat mCRPC that may impair kidney function, due to PSMA expression on proximal tubular cells and urinary excretion of the radiopharmaceutical. While a short-term decline in estimated glomerular filtration rate (eGFR) has been …
us
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Ronit Juthani, Caiwei Zhong, W. Xie, Hailey Stoltenberg et autres
207 Background: LuPSMA has a proven clinical benefit in mCRPC, but there is a need to develop predictive and prognostic biomarkers of response. Neutrophil:lymphocyte ratio (NLR) has shown prognostic value across a range of therapies for solid tumors, but there is limited …
us
(code pays fourni par la source)
2025
article
OpenAlex
Meryam Losee, Mofei Liu, Su-Chun Cheng, Arda Könik et autres
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Avina Rami, Daniel Sentana Lledo, M. Muniz, Irbaz Bin Riaz et autres
us
(code pays fourni par la source)
2025
article
OpenAlex
Thomas S.C. Ng, Mofei Liu, Matthew Robertson, Arda Könik et autres
us, cn
(code pays fourni par la source)
2025
article
OpenAlex
Meryam Losee, Michael P. Kavanaugh, Mofei Liu, Nuno Borges et autres
BACKGROUND: Lu-PSMA-617, LuPSMA) improves overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) after at least one taxane chemotherapy and androgen receptor pathway inhibitor. There are limited data on the clinical course and outcomes of patients with mCRPC after receipt of …
us
(code pays fourni par la source)
2025
article
OpenAlex
Praful Ravi, Wanling Xie, Paul Morgan, Erin Healy et autres
TPS304 Background: LuPSMA is a proven life-prolonging therapy in men with metastatic castrate-resistant prostate cancer (mCRPC) who have previously received a taxane and an androgen receptor pathway inhibitor (ARPI). Despite patient selection by PSMA-PET/CT, responses are only seen in 50% of patients …
us
(code pays fourni par la source)
2025
article
OpenAlex
Narmeen S Rashid, Avina Rami, Min Lang, Hailey Stoltenberg et autres
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Avina Rami, Narmeen S Rashid, Caiyun Zhong, Wanling Xie et autres
BACKGROUND: Lu-prostate-specific membrane antigen (PSMA)-617 (LuPSMA) is a radionuclide therapy approved for patients with PSMA-avid metastatic castrate-resistant prostate cancer (mCRPC). We evaluated whether alterations in the DNA damage repair (DDR) pathway were associated with outcomes to LuPSMA. PATIENTS AND METHODS: We identified …
us
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Avina Rami, Thomas S.C. Ng, Emily Rothmann, Hailey Stoltenberg et autres
27 Background: Prior work suggests that African American (AA) and other minority patients (pts) derive equal benefit from taxane chemotherapy and androgen receptor pathway inhibitors (ARPIs) for mCRPC as white pts. LuPSMA showed an overall survival (OS) benefit in mCRPC pts after …
us
(code pays fourni par la source)